Clinical News
eMediNexus Coverage from: 
The first targeted therapy for metastatic bladder cancer
eMediNexus,  14 April 2019
remove_red_eye 83 Views
#Oncology #Urology

0 Read Comments                

The US Food and Drug Administration (FDA) has granted accelerated approval to Balversa (erdafitinib), a treatment for adult patients with locally advanced or metastatic bladder cancer that has a type of susceptible genetic alteration known as FGFR3 or FGFR2, and that has progressed during or following prior platinum-containing chemotherapy. Patients should be selected for therapy with Balversa using an FDA-approved companion diagnostic device. 
To continue reading this article
Sign in with Medtalks

Continue reading your article with a eMediNexus account.
Free Membership!